. . "Arteri\u00E1ln\u00ED hypertenze a chronick\u00E9 srde\u010Dn\u00ED selh\u00E1n\u00ED" . "187123" . . "3"^^ . . "CZ - \u010Cesk\u00E1 republika" . . "13" . . "Arteri\u00E1ln\u00ED hypertenze a chronick\u00E9 srde\u010Dn\u00ED selh\u00E1n\u00ED"@cs . "Hegarov\u00E1, Mark\u00E9ta" . "3" . "chronic heart failure; reverse myocardial remodelling; escape phenomenon; aliskiren"@en . . . "N" . "Arterial hypertension and chronic heart failure"@en . . "RIV/00023001:_____/11:00002574!RIV12-MZ0-00023001" . "Intern\u00ED medic\u00EDna pro praxi" . "Arteri\u00E1ln\u00ED hypertenze a chronick\u00E9 srde\u010Dn\u00ED selh\u00E1n\u00ED"@cs . . "Farmakoterapie esenci\u00E1ln\u00ED arteri\u00E1ln\u00ED hypertenze p\u0159edstavuje \u00FA\u010Dinnou prevenci rozvoje remodelace myokardu a vzniku chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (CHSS). Pokud nen\u00ED i p\u0159i zaveden\u00E9 farmakoterapii CHSS krevn\u00ED tlak dob\u0159e kontrolov\u00E1n, je v\u017Edy indikace k dal\u0161\u00EDmu l\u00E9\u010Debn\u00E9mu ovlivn\u011Bn\u00ED. K dispozici je kombina\u010Dn\u00ED l\u00E9\u010Dba inhibitory RAAS syst\u00E9mu, ACE-I a ARB za p\u0159\u00EDsn\u00E9 kontroly kalemie a ledvinov\u00FDch funkc\u00ED. Z toho postupu maj\u00ED prosp\u011Bch zejm\u00E9na pacienti s nad\u011Bj\u00ED na reverzn\u00ED remodelaci myokardu a nemocn\u00ED v pokro\u010Dilej\u0161\u00EDch f\u00E1z\u00EDch onemocn\u011Bn\u00ED dlouhodob\u011B l\u00E9\u010Deni ACE-I, u nich\u017E p\u0159edpokl\u00E1d\u00E1me fenom\u00E9n \u00FAniku. Novou velmi nad\u011Bjnou mo\u017Enost p\u0159edstavuje p\u0159id\u00E1n\u00ED p\u0159\u00EDm\u00E9ho inhibitoru reninu-aliskirenu, jeho\u017E efekt na ovlivn\u011Bn\u00ED mortality nemocn\u00FDch s CHSS mus\u00ED b\u00FDt je\u0161t\u011B potvrzen. Pokud nelze kombinovanou blok\u00E1dou RAAS dos\u00E1hnout normalizace krevn\u00EDho tlaku, nebo nen\u00ED tato l\u00E9\u010Dba tolerov\u00E1na, p\u0159ich\u00E1z\u00ED v \u00FAvahu p\u0159id\u00E1n\u00ED amlodipinu. Centr\u00E1ln\u00ED sympatolytika nejsou vhodn\u00E1. Podstatn\u00E9 je vylou\u010Dit mo\u017Enou odstranitelnou p\u0159\u00ED\u010Dinu hypertenze." . "1"^^ . "[F859BF9A5E6E]" . "Farmakoterapie esenci\u00E1ln\u00ED arteri\u00E1ln\u00ED hypertenze p\u0159edstavuje \u00FA\u010Dinnou prevenci rozvoje remodelace myokardu a vzniku chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (CHSS). Pokud nen\u00ED i p\u0159i zaveden\u00E9 farmakoterapii CHSS krevn\u00ED tlak dob\u0159e kontrolov\u00E1n, je v\u017Edy indikace k dal\u0161\u00EDmu l\u00E9\u010Debn\u00E9mu ovlivn\u011Bn\u00ED. K dispozici je kombina\u010Dn\u00ED l\u00E9\u010Dba inhibitory RAAS syst\u00E9mu, ACE-I a ARB za p\u0159\u00EDsn\u00E9 kontroly kalemie a ledvinov\u00FDch funkc\u00ED. Z toho postupu maj\u00ED prosp\u011Bch zejm\u00E9na pacienti s nad\u011Bj\u00ED na reverzn\u00ED remodelaci myokardu a nemocn\u00ED v pokro\u010Dilej\u0161\u00EDch f\u00E1z\u00EDch onemocn\u011Bn\u00ED dlouhodob\u011B l\u00E9\u010Deni ACE-I, u nich\u017E p\u0159edpokl\u00E1d\u00E1me fenom\u00E9n \u00FAniku. Novou velmi nad\u011Bjnou mo\u017Enost p\u0159edstavuje p\u0159id\u00E1n\u00ED p\u0159\u00EDm\u00E9ho inhibitoru reninu-aliskirenu, jeho\u017E efekt na ovlivn\u011Bn\u00ED mortality nemocn\u00FDch s CHSS mus\u00ED b\u00FDt je\u0161t\u011B potvrzen. Pokud nelze kombinovanou blok\u00E1dou RAAS dos\u00E1hnout normalizace krevn\u00EDho tlaku, nebo nen\u00ED tato l\u00E9\u010Dba tolerov\u00E1na, p\u0159ich\u00E1z\u00ED v \u00FAvahu p\u0159id\u00E1n\u00ED amlodipinu. Centr\u00E1ln\u00ED sympatolytika nejsou vhodn\u00E1. Podstatn\u00E9 je vylou\u010Dit mo\u017Enou odstranitelnou p\u0159\u00ED\u010Dinu hypertenze."@cs . "Pharmacotherapy of the essential hypertension is the effective prevention of the development of chronic heart failure (CHF). If blood pressure is not even in the complete heart failure pharmacotherapy well controlled, it is the indication for further therapeutic influence. A combination of treatment is available ? with inhibitors of RAAS system, ACE-I and ARB under strict control of potassium levels and renal functions. This approach will benefit in particular patients with hope to myocardial reverse remodeling and in patiens in advanced stages of a disease, receiving ACE-I in the long term with assumptive escape phenomenon. New option is to add a renin-direct inhibitor aliskiren, whose effect on the mortality must still be confirmed. If we cannot achieve normalisation of blood presure despite combined block of RAAS or is this treatment intolerable, addition of amlodipine is possible. Central sympathetic inhibitors are not advisable. It is essential to exclude a secondary hypertension."@en . "Arterial hypertension and chronic heart failure"@en . "1212-7299" . "RIV/00023001:_____/11:00002574" . . "1"^^ . . . . "Arteri\u00E1ln\u00ED hypertenze a chronick\u00E9 srde\u010Dn\u00ED selh\u00E1n\u00ED" . . .